Trade CNS Pharmaceuticals, Inc. - CNSP CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0198 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.196 |
| Open | 0.195 |
| 1-Year Change | -89.37% |
| Day's Range | 0.189 - 0.1955 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 0.1950 | 0.0000 | 0.00% | 0.1950 | 0.1993 | 0.1890 |
| Apr 24, 2024 | 0.1960 | 0.0009 | 0.46% | 0.1951 | 0.2035 | 0.1909 |
| Apr 23, 2024 | 0.1900 | -0.0050 | -2.56% | 0.1950 | 0.2048 | 0.1861 |
| Apr 22, 2024 | 0.1915 | 0.0054 | 2.90% | 0.1861 | 0.1950 | 0.1861 |
| Apr 19, 2024 | 0.1963 | 0.0018 | 0.93% | 0.1945 | 0.1988 | 0.1862 |
| Apr 18, 2024 | 0.1990 | 0.0100 | 5.29% | 0.1890 | 0.2041 | 0.1826 |
| Apr 17, 2024 | 0.1970 | -0.0029 | -1.45% | 0.1999 | 0.1999 | 0.1830 |
| Apr 16, 2024 | 0.2035 | -0.0235 | -10.35% | 0.2270 | 0.2270 | 0.1970 |
| Apr 15, 2024 | 0.2270 | -0.0203 | -8.21% | 0.2473 | 0.2500 | 0.2270 |
| Apr 12, 2024 | 0.2275 | -0.0026 | -1.13% | 0.2301 | 0.2417 | 0.2270 |
| Apr 11, 2024 | 0.2279 | -0.0011 | -0.48% | 0.2290 | 0.2333 | 0.2268 |
| Apr 10, 2024 | 0.2249 | 0.0050 | 2.27% | 0.2199 | 0.2250 | 0.2161 |
| Apr 9, 2024 | 0.2200 | -0.0050 | -2.22% | 0.2250 | 0.2326 | 0.2150 |
| Apr 8, 2024 | 0.2186 | -0.0513 | -19.01% | 0.2699 | 0.2699 | 0.2124 |
| Apr 5, 2024 | 0.2522 | -0.0276 | -9.86% | 0.2798 | 0.2798 | 0.2456 |
| Apr 4, 2024 | 0.2765 | -0.0092 | -3.22% | 0.2857 | 0.2880 | 0.2714 |
| Apr 3, 2024 | 0.2800 | -0.0163 | -5.50% | 0.2963 | 0.2994 | 0.2708 |
| Apr 2, 2024 | 0.3015 | -0.0485 | -13.86% | 0.3500 | 0.3500 | 0.2950 |
| Apr 1, 2024 | 0.3460 | -0.0145 | -4.02% | 0.3605 | 0.3675 | 0.3359 |
| Mar 28, 2024 | 0.3733 | 0.0083 | 2.27% | 0.3650 | 0.3733 | 0.3450 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
CNS Pharmaceuticals, Inc. Company profile
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals Inc. is a clinical pharmaceutical company. The Company is focused on development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The Company is developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, CNS Pharmaceuticals Inc revenues was not reported. Net loss increased 48% to $14M. Higher net loss reflects Research and development increase of 85% to $9.3M (expense), Selling/General/Admin Expense increase of 7% to $4.7M (expense), Interest expense increase from $3K to $9K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.57 to -$0.53.
| Industry: | Biotechnology & Medical Research (NEC) |
2100 West Loop S Ste 900
HOUSTON
TEXAS 77027-3522
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com